Ep. 256, Chapter 6: Biomarkers, Endpoints, And The Future of Psychedelic Therapies With Srinivas Rao

41:32 – End

Dr. Srinivas Rao notes that validated biomarkers and regulatory endpoints for mental health conditions like depression would be transformative, however despite promising signs from psychedelic research, they have not yet been verified. He also discusses whether the hallucinatory aspect of psychedelics, i.e., the trip, is necessary, noting that the experience most likely plays a role in disrupting entrenched neural patterns and promoting neuroplasticity. Ultimately, he believes psychedelic therapies, especially short-duration ones, have the potential to reshape mental health treatment by offering rapid, effective relief.